Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Glofitamab by F. Hoffmann-La Roche for Mantle Cell Lymphoma: Likelihood of Approval
Glofitamab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Mantle Cell Lymphoma. According to...
Glofitamab by F. Hoffmann-La Roche for Marginal Zone B-cell Lymphoma: Likelihood of Approval
Glofitamab is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Marginal Zone B-cell Lymphoma. According...
Glofitamab by F. Hoffmann-La Roche for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
Glofitamab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for B-Cell Non-Hodgkin Lymphoma. According to...
Glofitamab by F. Hoffmann-La Roche for Non-Hodgkin Lymphoma: Likelihood of Approval
Glofitamab is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData,...
Glofitamab by F. Hoffmann-La Roche for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Glofitamab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Chronic Lymphocytic Leukemia (CLL). According...